Orient Europharma Co (ROCO:4120) Debt-to-Equity : 1.31 (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Orient Europharma Co Debt-to-Equity?

Orient Europharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$2,937 Mil. Orient Europharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$1,969 Mil. Orient Europharma Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NT$3,754 Mil. Orient Europharma Co's debt to equity for the quarter that ended in Mar. 2024 was 1.31.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Orient Europharma Co's Debt-to-Equity or its related term are showing as below:

ROCO:4120' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.18 Med: 0.51 Max: 1.72
Current: 1.31

During the past 13 years, the highest Debt-to-Equity Ratio of Orient Europharma Co was 1.72. The lowest was 0.18. And the median was 0.51.

ROCO:4120's Debt-to-Equity is ranked worse than
89.94% of 845 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs ROCO:4120: 1.31

Orient Europharma Co Debt-to-Equity Historical Data

The historical data trend for Orient Europharma Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orient Europharma Co Debt-to-Equity Chart

Orient Europharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.65

0.75

1.44

1.72

1.38

Orient Europharma Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															1.67	1.61	1.49	1.38	1.31

Competitive Comparison of Orient Europharma Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Orient Europharma Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orient Europharma Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orient Europharma Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Orient Europharma Co's Debt-to-Equity falls into.

Orient Europharma Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Orient Europharma Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2639.476	+	2202.976)	/	3514.485
	=	1.38

Orient Europharma Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2937.289	+	1969.039)	/	3753.868
	=	1.31

Orient Europharma Co (ROCO:4120) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Orient Europharma Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Orient Europharma Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Orient Europharma Co (ROCO:4120) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orient Europharma Co Ltd (ROCO:4120) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

13F., No. 128, Chengde Rd., Sec. 6,, Beitou Distrit, Taipei, TWN, 112052

Website

https://www.oep.com.tw

Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of f Western Pharmaceutical and Medical Devices. The firm also Manufacture Drugs and Medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements.

Orient Europharma Co (ROCO:4120) Headlines

No Headlines